{"gene":"FGF1","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2003,"finding":"FGF1 non-classical export (lacking an N-terminal signal sequence) depends on Cu2+-dependent formation of multiprotein complexes containing the S100A13 protein, and the protein may translocate across the membrane as a 'molten globule'.","method":"Biochemical characterization of export complex components; copper chelation inhibition experiments","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple labs reporting S100A13 involvement, but abstract-level description limits mechanistic detail","pmids":["14625381"],"is_preprint":false},{"year":2007,"finding":"Sphingosine kinase 1 (SphK1) is a component of the copper-dependent FGF1 non-classical export pathway: SphK1 forms a complex with FGF1 in a cell-free system in a copper-dependent manner, SphK1-null cells fail to release FGF1 under stress, and SphK1 overexpression rescues FGF1 release from inhibition by a copper chelator.","method":"Cell-free complex reconstitution, SphK1 knockout/overexpression, copper chelation rescue experiments","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-free reconstitution and genetic rescue, single lab","pmids":["17643421"],"is_preprint":false},{"year":2000,"finding":"Translocation of exogenous aFGF from the cell surface to the cytosol and nucleus requires phosphatidylinositol 3-kinase (PI3K) activity; inhibition of PI3K by chemical inhibitors or dominant-negative PI3K blocks cytosolic and nuclear translocation of aFGF, and PI3K-inhibited cells retain a diphtheria toxin–aFGF fusion protein in the cytosol rather than allowing nuclear entry.","method":"PI3K chemical inhibition, dominant-negative PI3K expression, cell fractionation, farnesylation and PKC phosphorylation reporters for translocation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods (chemical inhibition, dominant-negative genetics, reporter translocation assays) in a single study","pmids":["10766827"],"is_preprint":false},{"year":2012,"finding":"Nuclear import of exogenous FGF1 (after cytosolic translocation) requires the ER-anchored protein LRRC59, Ran GTPase, importin-α1 (Kpnα1), and importin-β1 (Kpnβ1), as well as a nuclear localization sequence (NLS) in FGF1. LRRC59 depletion by siRNA does not block cytosolic translocation but blocks nuclear import of FGF1; nuclear import of FGF2 is independent of LRRC59 but dependent on the same importins.","method":"siRNA knockdown of LRRC59, Kpnα1, Kpnβ1; cell fractionation; localization imaging; comparison with FGF2 import pathway","journal":"Traffic (Copenhagen, Denmark)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple siRNA knockdowns with orthogonal readouts, including pathway comparison to discriminate specificity","pmids":["22321063"],"is_preprint":false},{"year":2014,"finding":"Nucleolin binds directly to FGF1 (interaction confirmed by surface plasmon resonance and pulldown) at residues within the heparin-binding site; nucleolin is required for intranuclear phosphorylation of FGF1 by PKCδ, and this phosphorylation event is required for nuclear export of FGF1. In nucleolin-depleted cells, FGF1 enters the nucleus but is neither phosphorylated by PKCδ nor exported.","method":"Affinity pulldown, surface plasmon resonance, nucleolin siRNA depletion, FGF1 phosphomimetic and binding mutants, nuclear fractionation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding confirmed by SPR, mechanistic pathway confirmed with multiple mutants and knockdown, single lab","pmids":["24595027"],"is_preprint":false},{"year":2009,"finding":"FGF1 nuclear translocation (via its NLS) is required for both its neurotrophic/differentiation activity and its protection against p53-dependent apoptosis in PC12 cells; deletion of the NLS (FGF1ΔNLS) abolishes nuclear localization and both activities. Wild-type FGF1 interacts with p53 (co-immunoprecipitation), whereas ΔNLS-FGF1 does not.","method":"Transfection of FGF1 NLS-deletion mutants, nuclear fractionation/imaging, co-immunoprecipitation of FGF1 with p53, differentiation and survival assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutant transfection with functional readouts plus co-IP, single lab","pmids":["19765618"],"is_preprint":false},{"year":2005,"finding":"Intracellular (intracrine) FGF1 inhibits p53-dependent apoptosis and cell growth arrest via an intracrine pathway; it increases MDM2 expression (mRNA and protein), accelerating p53 degradation, and prevents Bax transactivation by p53. p53 activation represses FGF1 gene expression. Extracellular FGF1 has no effect on p53-dependent pathways.","method":"Transfection of intracellular vs. extracellular FGF1 constructs in rat embryonic fibroblasts; apoptosis/cell cycle assays; Western blot and RT-PCR for MDM2 and p53 targets","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic gain-of-function with multiple downstream readouts, single lab","pmids":["16091747"],"is_preprint":false},{"year":2016,"finding":"FGF1 C-terminal residue K132 and phosphorylation of S130 regulate intracrine FGF1 anti-apoptotic activity in PC12 cells: K132E mutation abolishes both neurotrophic and anti-apoptotic activities; FGF1(S130A) (non-phosphorylatable) protects against p53-dependent apoptosis, whereas FGF1(S130D) (phosphomimetic) does not, indicating that phosphorylation inhibits anti-apoptotic activity but does not affect neurotrophic/differentiation activity.","method":"Transfection of FGF1 point mutants (K132E, S130A, S130D) in PC12 cells; differentiation and apoptosis assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic mutagenesis with differentiated functional readouts, single lab","pmids":["26844696"],"is_preprint":false},{"year":2017,"finding":"FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation at S130 and the C-terminal domain (K132). FGF1 phosphorylation status determines intracrine (but not extracellular pathway) anti-apoptotic activity; this effect is cell-type specific (absent in N2a cells).","method":"Recombinant FGF1 addition and FGF1 overexpression with point mutants (K132E, S130A, S130D) in SH-SY5Y and N2a cells; apoptosis assays; etoposide treatment","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic mutagenesis with orthogonal cell-type comparison, single lab","pmids":["29048426"],"is_preprint":false},{"year":2018,"finding":"Intracellular FGF1 (translocated from endosomes into the cytosol/nucleus) protects cells against apoptosis independently of FGFR activation and downstream signaling; this anti-apoptotic effect is abolished by inhibitors of endosome-to-cytosol translocation but not by potent FGFR kinase inhibitors. FGF1 mutations preventing binding to nucleolin (thereby preventing nuclear phosphorylation) reduce the anti-apoptotic activity, linking nuclear phosphorylation to anti-apoptotic function.","method":"FGFR kinase inhibitors, FGFR1 kinase-dead mutant, translocation inhibitors, nucleolin-binding FGF1 mutants; serum starvation and staurosporine apoptosis assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal pharmacological and genetic perturbations dissecting receptor-dependent vs. receptor-independent activities, replicated across multiple cell lines","pmids":["30099027"],"is_preprint":false},{"year":2015,"finding":"AHNAK2 associates with FGF1 in a heat-shock-dependent manner (identified by co-immunoprecipitation/mass spectrometry); AHNAK2 depletion drastically decreases stress-induced FGF1 export but does not affect spontaneous FGF2 export or Notch-inhibition-induced FGF1 release, placing AHNAK2 specifically in the stress-induced non-classical FGF1 export pathway.","method":"Immunoprecipitation/mass spectrometry, AHNAK2 siRNA depletion, subcellular fractionation, FGF1 export assays under heat shock","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP/MS identification plus functional siRNA validation, single lab","pmids":["25560297"],"is_preprint":false},{"year":2011,"finding":"Non-classical FGF1 release and FGF1-dependent cell transformation are regulated by Notch signaling through transcription factor CBF1: dominant-negative CBF1 induces FGF1 and SphK1 transcription and stimulates stress-independent FGF1 release; the transformed phenotype of dnCBF1 cells is blocked by dominant-negative FGFR1 or dominant-negative S100A13; FGF1 export and cell proliferation induced by dnCBF1 depend on SphK1.","method":"Dominant-negative CBF1 and MAML transfection, colony formation assay, tumor xenograft, FGF1 export assay, FGF1-null cells","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis using dominant-negative constructs and null cells, multiple phenotypic readouts, single lab","pmids":["21302306"],"is_preprint":false},{"year":1996,"finding":"FGF1 neurotrophic activity (neuronal differentiation and serum-free survival) in PC12 cells requires endogenous FGF1 expression and is independent of the MAP kinase cascade; MAP kinase (ERK1) is activated equally by FGF1, FGF1+heparin, and a mutated FGF1, but only FGF1+heparin promotes differentiation. Constitutive or inducible overexpression of FGF1 directly promotes differentiation and survival proportional to the level of FGF1 expressed.","method":"MAP kinase activation assays, PC12 differentiation assays, FGF1 transfection with constitutive and inducible expression vectors, serum-free survival","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical pathway dissection with transfection gain-of-function, single lab","pmids":["8576258"],"is_preprint":false},{"year":2017,"finding":"An FGF1 partial agonist carrying triple mutations (FGF1ΔHBS) that diminish heparan sulfate (HS)-assisted FGFR dimerization has severely reduced mitogenic/proliferative activity while retaining full metabolic activity; this establishes that stable FGFR dimerization is required for mitogenesis but suboptimal FGFR activation by a weak FGF1-FGFR dimer is sufficient for metabolic responses (glucose homeostasis).","method":"Site-directed mutagenesis of heparin-binding site, in vitro proliferation assays, in vivo metabolic assays in mice, receptor dimerization assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution-level mutagenesis with orthogonal in vitro and in vivo functional dissection of two distinct biological activities","pmids":["28813681"],"is_preprint":false},{"year":2022,"finding":"FGF1 acutely suppresses adipose lipolysis and hepatic glucose production by inhibiting the cAMP-PKA axis through activation of phosphodiesterase 4D (PDE4D), which is mechanistically distinct from insulin's inhibitory action via PDE3B. FGF1-induced Ser44 phosphorylation of PDE4D is a regulatory site modulated by the feed-fast cycle.","method":"In vivo FGF1 administration with lipolysis and hepatic glucose production assays; phosphodiesterase activity assays; phosphoproteomics identifying PDE4D Ser44; pharmacological PDE4 inhibition","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical and in vivo methods, identification of specific phosphorylation site, mechanistic distinction from insulin pathway","pmids":["34986332"],"is_preprint":false},{"year":2022,"finding":"FGF1 increases glucose uptake in adipocytes via two mechanisms: acutely, through MEK1/2 and Akt crosstalk activating the insulin-sensitive glucose transporter GLUT4; and with prolonged exposure, through MEK1/2-dependent transcriptional upregulation of the basal glucose transporter GLUT1. FGF1 knockout mice have reduced adipose glucose uptake.","method":"FGF1 treatment of 3T3-L1 adipocytes and ex vivo adipose explants; FGF1 knockout mice; MEK1/2 and Akt inhibitors; GLUT1/GLUT4 expression and trafficking assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse phenotype confirmed in ex vivo and in vitro, pharmacological pathway dissection, multiple orthogonal readouts","pmids":["36161959"],"is_preprint":false},{"year":2020,"finding":"In adipocytes, mechanical activation of Piezo1 causes release of FGF1, which then induces preadipocyte differentiation (adipogenesis) through activation of FGF receptor 1 (FGFR1). Mice lacking Piezo1 in mature adipocytes show defective preadipocyte differentiation under high-fat diet.","method":"Adipocyte-specific Piezo1 knockout mice on high-fat diet; FGF1 release assays; FGFR1 activation assays; preadipocyte differentiation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout mouse with clearly defined cellular phenotype and receptor-ligand pathway validated, replicated across conditions","pmids":["32385276"],"is_preprint":false},{"year":2015,"finding":"In zebrafish, Fgf1 signaling is necessary and sufficient for overnutrition-induced compensatory β-cell differentiation: fgf1 inactivation abolishes compensatory β-cell differentiation; expression of human FGF1 solely in β-cells rescues the response in fgf1-/- animals; constitutive FGF1 secretion with an exogenous signal peptide increases β-cell number without overnutrition. FGF1 is secreted from β-cells during prolonged activation, with ER stress acting upstream of FGF1 release.","method":"Zebrafish fgf1 loss-of-function and rescue genetics, constitutive FGF1 secretion construct, small-molecule screen, β-cell differentiation assay, ER stress manipulation","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic necessity and sufficiency established with rescue experiments, orthologous context consistent with mammalian FGF1","pmids":["26420862"],"is_preprint":false},{"year":2014,"finding":"FGFR-1 interacts with the TNF receptor superfamily member Fn14 (co-immunoprecipitation and proximity ligation assay in cardiomyocytes); FGF1-induced cardiomyocyte cell cycle reentry is blocked by Fn14 inhibition, and TWEAK-induced cell cycle activation is blocked by FGFR-1 inhibition; costimulation with FGF1 and TWEAK synergistically induces cell cycle reentry via PI3K/Akt signaling.","method":"Co-immunoprecipitation, proximity ligation assay, Fn14 siRNA inhibition, FGFR-1 blockade, PI3K/Akt pathway analysis, cardiomyocyte cell cycle assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction confirmed by two orthogonal methods plus functional blockade, single lab","pmids":["24571920"],"is_preprint":false},{"year":2002,"finding":"Cardiac-specific overexpression of FGF1 in transgenic mice delays infarct development and provides cardiomyocyte-level protection independently of angiogenesis, at least partially through constitutively elevated ERK-1/2 activity; ERK-1/2 inhibitor (UO126) reduces the cardioprotective effect.","method":"Transgenic mouse coronary occlusion model, infarct size measurement, ERK-1/2 Western blot, ERK inhibitor treatment, isolated cardiomyocyte ischemia simulation","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse model with pharmacological pathway validation, multiple readouts, single lab","pmids":["12176126"],"is_preprint":false},{"year":2016,"finding":"Cell-surface-localized importin α1 (KPNA2) binds directly to FGF1 (a cNLS-containing growth factor) and enhances ERK1/2 activation downstream of FGF1 signaling; anti-importin α1 antibody suppresses FGF1-importin α1 complex formation and ERK1/2 activation, reducing cancer cell proliferation.","method":"Cell surface importin α1 detection, co-immunoprecipitation of importin α1 with FGF1, ERK1/2 phosphorylation assays, anti-importin α1 antibody inhibition, proliferation assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding shown by co-IP, functional consequence confirmed by antibody blockade, single lab","pmids":["26887791"],"is_preprint":false},{"year":2018,"finding":"FGF1 binds cell-surface proteoglycans CSPG4 (NG2) and CD44 in addition to FGFRs; FGF1 binds CD44 through its heparin-binding moiety; both CSPG4 and CD44 colocalize with FGF1 at the cell surface and likely act as storage/reservoir molecules for FGF1.","method":"APEX2-FGF1 proximity labeling on living cells followed by proteomics; signaling validation of fusion protein; colocalization imaging; heparin-binding domain mutant analysis","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity labeling plus domain-mapping mutagenesis and colocalization, single lab","pmids":["29812912"],"is_preprint":false},{"year":1991,"finding":"Both high-affinity aFGF (and bFGF) binding and receptor activation by aFGF/bFGF do not require the N-terminal first Ig-like domain and acidic motif of the FGFR (bek/FGFR2); a truncated bek variant lacking these regions is sufficient for high-affinity binding and cell activation.","method":"cDNA cloning and overexpression of truncated FGFR variants in NIH3T3 cells; FGF binding assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor domain deletion with ligand-binding and activation readouts, single study","pmids":["1722570"],"is_preprint":false},{"year":1995,"finding":"aFGF and bFGF induce membrane ruffling in breast cancer cells (but not normal breast epithelial cells) through FGFR-4; dominant-negative FGFR-3 or dominant-negative p21rac inhibits membrane ruffling, establishing that receptor dimerization/phosphorylation and Rac activation are prerequisites; transient transfection showed FGFR-1, -2, -3 cannot mediate ruffling while FGFR-4 can.","method":"Dominant-negative FGFR3 and Rac transfection, transient transfection of individual FGFRs in COS-7 cells, morphological membrane ruffling assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative genetics and receptor isoform transfection, single lab","pmids":["7534069"],"is_preprint":false},{"year":2001,"finding":"FGF-1 (and FGF-2) upregulate E-cadherin, β-catenin, and α-catenin protein levels in pancreatic cancer cells and facilitate the association of E-cadherin and α-catenin with the cytoskeleton (shown by increased detergent-insoluble fraction). FGFs also elevate tyrosine phosphorylation of E-cadherin, α-, β-, and γ-catenins (but not p120ctn), suggesting FGF/FGFR signaling regulates the E-cadherin/catenin complex.","method":"FGF-1 treatment of pancreatic cancer cell lines, Western blot for cadherin/catenin levels, Triton X-100 fractionation for cytoskeletal association, tyrosine phosphorylation Western blot","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple cell lines and multiple biochemical readouts but no genetic confirmation, single lab","pmids":["11745459"],"is_preprint":false},{"year":2019,"finding":"Both Erk1/2 and p38 kinase phosphorylate FRS2 (a major FGFR1 signaling mediator) as part of negative-feedback downregulation of FGF1-induced signaling. Simultaneous inhibition of both Erk1/2 and p38 produces significantly prolonged FGFR1 and FRS2 tyrosine phosphorylation compared to Erk inhibition alone, and excessive p38 activation can partially compensate for absent Erk activity.","method":"Pharmacological inhibition of Erk1/2 and/or p38 in NIH3T3 and U2OS-FGFR1 cells; anisomycin p38 activation; Western blot for FGFR1 and FRS2 phosphorylation","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway crosstalk with orthogonal activator/inhibitor design, single lab","pmids":["31013829"],"is_preprint":false},{"year":2013,"finding":"The FGF1 gene 1B promoter is activated by valproic acid (VPA) through inhibition of HDAC (histone deacetylases) and GSK-3 activities; VPA causes increased histone H3 acetylation at an 18-bp cis-element of the FGF-1B promoter and alters RFX1-3 transcriptional complex binding.","method":"FGF-1B promoter-GFP reporter, HDAC and GSK-3 inhibitors (sodium butyrate, trichostatin A, lithium), GSK-3 siRNA, ChIP for histone acetylation","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitors and siRNA confirmed with ChIP, single lab","pmids":["23647222"],"is_preprint":false},{"year":2012,"finding":"RFX1, RFX2, and RFX3 transcription factors directly bind an 18-bp cis-element (-484 to -467) in the human FGF1 gene 1B promoter to regulate its activity; RFX2/RFX3 complex is detected only in FGF-1B positive cells; RFX2 knockdown reduces FGF-1B(+) cell proportion and neurosphere formation while RFX2 overexpression has opposite effects.","method":"Promoter-reporter assays, ChIP/EMSA for RFX binding, RFX2 siRNA knockdown and overexpression, neurosphere assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed, genetic gain/loss-of-function, single lab","pmids":["22415835"],"is_preprint":false},{"year":2023,"finding":"FGF1 ameliorates hepatic steatosis by inducing IGFBP2 expression through reducing recruitment of DNA methyltransferase 3α (DNMT3A) to the IGFBP2 genomic locus, decreasing IGFBP2 gene methylation and increasing its expression; AAV-mediated IGFBP2 suppression diminishes the therapeutic benefit of FGF1 on hepatic steatosis, demonstrating that this epigenetic IGFBP2 pathway mediates FGF1 metabolic action.","method":"Recombinant FGF1 treatment in HFD mice, ChIP for DNMT3A at IGFBP2 locus, bisulfite sequencing for methylation, AAV-IGFBP2 knockdown epistasis, palmitic acid hepatocyte model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and methylation analysis with in vivo epistasis, single lab","pmids":["36934380"],"is_preprint":false},{"year":2016,"finding":"FGF1/FGFR signaling activates Aurora A (AurA) kinase (Thr288 phosphorylation) in glioblastoma cells; FGFR inhibitor (SU5402) down-regulates AurA activity and AurA inhibitors reduce neurosphere formation and induce neuronal differentiation of FGF1B(+) GBM cells.","method":"FGF1 treatment and FGFR inhibition in GBM cell lines, AurA phosphorylation Western blot, FACS isolation of F1BGFP+ cells, neurosphere assays, AurA inhibitors","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition of FGFR and AurA with multiple orthogonal functional readouts, single lab","pmids":["27138904"],"is_preprint":false},{"year":2021,"finding":"FGF1ΔHBS (reduced heparin-binding, low-mitogenicity variant) protects against diabetic cardiomyopathy by activating AMPK, which suppresses Nur77 expression, leading to reduced mitochondrial fragmentation, ROS, and cytochrome c leakage and enhanced mitochondrial respiration; protective effects are absent in AMPK-null mice, establishing AMPK as a required downstream mediator.","method":"db/db mouse model, FGF1ΔHBS administration, RNA-seq, AMPK knockout mice, mitochondrial function assays, ROS and apoptosis assays in vitro and in vivo","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — AMPK-null mouse epistasis confirms pathway requirement, multiple orthogonal in vitro and in vivo readouts, single lab","pmids":["33762571"],"is_preprint":false},{"year":1993,"finding":"aFGF binding to cell-surface receptors induces both high-affinity receptor (HAR/FGFR1) dimerization and aFGF homodimerization; the 150 kDa HAR-aFGF complex is proposed to consist of one FGFR1 associated with one heparan sulfate proteoglycan (LAR) via aFGF dimerization. Heparin suppresses formation of the 150 kDa complex and the aFGF dimer on LAR. An aFGF mutant with reduced heparin affinity does not promote dimerization. Only HAR (not LAR) directly mediates aFGF internalization.","method":"Cross-linking experiments with 125I-aFGF, receptor binding and internalization assays, heparin competition, aFGF mutant with reduced heparin affinity","journal":"Growth factors (Chur, Switzerland)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cross-linking and binding studies with heparin competition and mutant, single lab","pmids":["7686384"],"is_preprint":false},{"year":2022,"finding":"FGF1 promotes a glycolytic metabolic phenotype in endocrine-resistant breast cancer cells by stimulating estrogen receptor (ER) phosphorylation independently of estradiol; this estrogen-independent ER activation and metabolic reprogramming involves the FGF/FGFR axis.","method":"Untargeted proteomics, phospho-proteomics, gene expression profiling, functional metabolic assessments in breast cancer cells; validated in obese mouse tumor samples","journal":"Breast cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal omics and functional metabolic assays, single lab","pmids":["37608351"],"is_preprint":false}],"current_model":"FGF1 is a heparin-binding growth factor that signals through cell-surface FGF receptors (requiring HS-assisted FGFR dimerization for full mitogenic activation, while suboptimal dimerization is sufficient for metabolic responses), and also operates via a receptor-independent intracrine/nuclear pathway in which exogenous FGF1 is endocytosed, translocated to the cytosol via PI3K-dependent vesicular transport, imported into the nucleus via LRRC59/importin-α1/β1, where it interacts with nucleolin leading to PKCδ-mediated phosphorylation at S130 (which triggers nuclear export) and directly interacts with p53 to suppress apoptosis; metabolically, peripheral FGF1 acutely suppresses lipolysis and hepatic glucose production by activating PDE4D (suppressing cAMP-PKA signaling), promotes adipocyte glucose uptake through GLUT4/GLUT1 via MEK1/2-Akt crosstalk, and is released non-classically from cells without a signal peptide through a Cu2+- and S100A13-dependent pathway involving sphingosine kinase 1 and AHNAK2, regulated upstream by Notch/CBF1 signaling."},"narrative":{"mechanistic_narrative":"FGF1 is a heparin-binding growth factor that operates through two distinct arms: canonical signaling via cell-surface FGF receptors and a receptor-independent intracrine/nuclear pathway, and it has emerged as a potent regulator of systemic metabolism [PMID:28813681, PMID:34986332]. At the receptor, FGF1 binding induces FGFR and ligand homodimerization in a heparin-/heparan sulfate-dependent manner [PMID:7686384], and an engineered variant with diminished heparan-sulfate-assisted FGFR dimerization (FGF1ΔHBS) retains full metabolic activity while losing mitogenic potency, establishing that stable receptor dimerization drives proliferation whereas suboptimal dimerization suffices for metabolic responses [PMID:28813681]. Metabolically, peripheral FGF1 acutely suppresses adipose lipolysis and hepatic glucose production by activating phosphodiesterase 4D to inhibit the cAMP-PKA axis—mechanistically distinct from insulin's action via PDE3B [PMID:34986332]—and promotes adipocyte glucose uptake through MEK1/2-Akt crosstalk acting on GLUT4 and transcriptional induction of GLUT1 [PMID:36161959]. In a parallel intracrine route, exogenous FGF1 is endocytosed and translocated to the cytosol in a PI3K-dependent manner [PMID:10766827], imported into the nucleus via the ER-anchored protein LRRC59 together with importin-α1/β1 and Ran [PMID:22321063], where it binds nucleolin to enable PKCδ-mediated phosphorylation at S130 that triggers nuclear export [PMID:24595027]; nuclear FGF1 interacts with p53 and suppresses p53-dependent apoptosis independently of FGFR kinase activity [PMID:19765618, PMID:30099027]. FGF1 is secreted by a non-classical, signal-peptide-independent route that requires Cu2+-dependent assembly with S100A13, sphingosine kinase 1, and AHNAK2 [PMID:14625381, PMID:17643421, PMID:25560297], a pathway transcriptionally restrained by Notch/CBF1 signaling [PMID:21302306]. Across tissues these activities underlie roles in β-cell compensatory differentiation [PMID:26420862], cardiomyocyte protection and proliferation [PMID:12176126], adipogenesis downstream of mechanical Piezo1 activation [PMID:32385276], and reversal of hepatic steatosis [PMID:36934380].","teleology":[{"year":1991,"claim":"Defined which FGFR regions are dispensable for FGF1 high-affinity binding and activation, refining the receptor-ligand engagement model.","evidence":"truncated FGFR2 (bek) variant expression and binding assays in NIH3T3 cells","pmids":["1722570"],"confidence":"Medium","gaps":["Does not resolve the structural basis of dimerization","Single receptor isoform tested"]},{"year":1993,"claim":"Established that FGF1 receptor activation proceeds through heparin-modulated FGFR and ligand dimerization, defining the assembly logic of the signaling complex.","evidence":"crosslinking of 125I-aFGF, heparin competition, and a reduced-heparin-affinity mutant","pmids":["7686384"],"confidence":"Medium","gaps":["Complex stoichiometry inferred rather than structurally resolved","Role of specific heparan sulfate proteoglycan not defined"]},{"year":1996,"claim":"Showed FGF1 neurotrophic/survival activity can be uncoupled from MAP kinase activation, hinting at a receptor-independent intracellular mode.","evidence":"PC12 differentiation assays with FGF1 transfection and MAP kinase activation readouts","pmids":["8576258"],"confidence":"Medium","gaps":["Intracellular site of action not localized","Effector of the MAPK-independent activity unknown at this stage"]},{"year":2000,"claim":"Identified PI3K as a requirement for translocation of exogenous FGF1 from the cell surface to the cytosol and nucleus, opening the intracrine trafficking pathway.","evidence":"PI3K chemical inhibition, dominant-negative PI3K, cell fractionation and translocation reporters","pmids":["10766827"],"confidence":"High","gaps":["Identity of PI3K-dependent vesicular machinery undefined","Step at which FGF1 crosses the membrane unresolved"]},{"year":2003,"claim":"Characterized FGF1 non-classical export as a Cu2+-dependent multiprotein process involving S100A13, addressing how a signal-peptide-less protein is released.","evidence":"biochemical export complex characterization and copper chelation inhibition","pmids":["14625381"],"confidence":"Medium","gaps":["Molten-globule translocation mechanism not directly demonstrated","In vivo relevance of copper dependence unclear"]},{"year":2005,"claim":"Demonstrated that intracellular FGF1 suppresses p53-dependent apoptosis by raising MDM2 and blocking Bax transactivation, establishing an intracrine anti-apoptotic function.","evidence":"intracellular vs. extracellular FGF1 constructs in rat embryonic fibroblasts with apoptosis and target gene readouts","pmids":["16091747"],"confidence":"Medium","gaps":["Direct vs. indirect FGF1-p53 interaction not shown here","Mechanism of MDM2 induction undefined"]},{"year":2007,"claim":"Placed sphingosine kinase 1 in the copper-dependent FGF1 export complex, expanding the non-classical secretion machinery.","evidence":"cell-free reconstitution, SphK1 knockout/overexpression, copper-chelation rescue","pmids":["17643421"],"confidence":"Medium","gaps":["Enzymatic vs. structural role of SphK1 not separated","Single lab"]},{"year":2009,"claim":"Linked the FGF1 NLS to both neurotrophic and anti-apoptotic activity and showed wild-type but not ΔNLS FGF1 co-immunoprecipitates with p53.","evidence":"NLS-deletion mutants, fractionation/imaging, FGF1-p53 co-IP, survival assays in PC12 cells","pmids":["19765618"],"confidence":"Medium","gaps":["Direct binding not confirmed (co-IP only)","Whether nuclear entry alone or downstream events drive protection unresolved"]},{"year":2012,"claim":"Defined the nuclear import machinery for cytosolic FGF1 as LRRC59/importin-α1/β1/Ran, distinguishing it from FGF2 import.","evidence":"siRNA knockdown of LRRC59 and importins with fractionation and pathway comparison","pmids":["22321063"],"confidence":"High","gaps":["How ER-anchored LRRC59 hands off FGF1 to importins mechanistically unclear","Cytosol-to-nucleus shuttling kinetics undefined"]},{"year":2012,"claim":"Identified RFX1-3 transcription factors binding an 18-bp cis-element of the FGF1 1B promoter as direct regulators of FGF1 expression in neural cells.","evidence":"promoter-reporter, ChIP/EMSA, RFX2 knockdown/overexpression with neurosphere assays","pmids":["22415835"],"confidence":"Medium","gaps":["Tissue-specific signals controlling RFX complex assembly unknown","Other FGF1 promoters not addressed"]},{"year":2013,"claim":"Showed the FGF1 1B promoter is epigenetically activated via HDAC and GSK-3 inhibition through RFX-bound chromatin, connecting chromatin state to FGF1 induction.","evidence":"promoter reporter, HDAC/GSK-3 inhibitors, GSK-3 siRNA, histone acetylation ChIP","pmids":["23647222"],"confidence":"Medium","gaps":["Physiological stimulus engaging this axis unknown","Direct HDAC isoform not identified"]},{"year":2014,"claim":"Established nucleolin as a direct FGF1 partner required for PKCδ phosphorylation of FGF1 and subsequent nuclear export, defining the intranuclear processing step.","evidence":"SPR, affinity pulldown, nucleolin siRNA, FGF1 binding and phosphomimetic mutants, fractionation","pmids":["24595027"],"confidence":"High","gaps":["How nucleolin positions FGF1 for PKCδ not structurally resolved","PKCδ recruitment mechanism undefined"]},{"year":2014,"claim":"Identified an FGFR1-Fn14 receptor interaction enabling synergistic FGF1/TWEAK-driven cardiomyocyte cell cycle reentry via PI3K/Akt.","evidence":"co-IP, proximity ligation, Fn14 and FGFR-1 inhibition, cell cycle assays in cardiomyocytes","pmids":["24571920"],"confidence":"Medium","gaps":["Whether interaction is direct or scaffold-mediated unknown","In vivo relevance not tested"]},{"year":2015,"claim":"Added AHNAK2 as a stress-induced, heat-shock-dependent component specifically required for non-classical FGF1 (not FGF2) export.","evidence":"co-IP/MS identification, AHNAK2 siRNA, fractionation and export assays","pmids":["25560297"],"confidence":"Medium","gaps":["Molecular role of AHNAK2 in translocation unknown","Interplay with S100A13/SphK1 complex undefined"]},{"year":2015,"claim":"Demonstrated in zebrafish that Fgf1 is necessary and sufficient for overnutrition-induced compensatory β-cell differentiation, establishing a physiological metabolic role for secreted FGF1.","evidence":"fgf1 loss-of-function and β-cell rescue genetics, constitutive secretion construct, ER stress manipulation","pmids":["26420862"],"confidence":"High","gaps":["Receptor and downstream effectors in β-cells not defined here","Mammalian conservation inferred, not directly shown"]},{"year":2016,"claim":"Showed cell-surface importin α1 (KPNA2) binds FGF1 and enhances ERK1/2 activation and cancer cell proliferation, expanding importin function beyond nuclear import.","evidence":"surface importin α1 detection, FGF1 co-IP, antibody blockade, proliferation assays","pmids":["26887791"],"confidence":"Medium","gaps":["Mechanism by which surface importin potentiates ERK unclear","Relationship to FGFR signaling complex undefined"]},{"year":2016,"claim":"Linked FGF1/FGFR signaling to Aurora A activation controlling neurosphere formation and differentiation state in glioblastoma.","evidence":"FGF1 treatment, FGFR and AurA pharmacological inhibition, neurosphere assays in GBM cells","pmids":["27138904"],"confidence":"Medium","gaps":["Direct vs. indirect AurA activation undefined","Pharmacological inhibitors only"]},{"year":2016,"claim":"Mapped FGF1 K132 and S130 phosphorylation as switches controlling intracrine anti-apoptotic versus neurotrophic activities.","evidence":"K132E/S130A/S130D point mutants in PC12 cells with differentiation and apoptosis assays","pmids":["26844696"],"confidence":"Medium","gaps":["Structural consequence of phosphorylation not determined","Kinase responsible inferred from prior work"]},{"year":2017,"claim":"Confirmed the S130-phosphorylation-dependent, cell-type-specific intracrine anti-apoptotic pathway in neuroblastoma cells.","evidence":"recombinant and overexpressed FGF1 mutants in SH-SY5Y vs. N2a cells, etoposide apoptosis assays","pmids":["29048426"],"confidence":"Medium","gaps":["Basis of cell-type specificity unknown","Single lab"]},{"year":2017,"claim":"Separated mitogenic from metabolic FGF1 activity using FGF1ΔHBS, showing stable FGFR dimerization is required for proliferation but not for glucose homeostasis—a foundation for safer metabolic therapeutics.","evidence":"heparin-binding-site mutagenesis, in vitro proliferation and in vivo metabolic and dimerization assays","pmids":["28813681"],"confidence":"High","gaps":["Receptor signaling differences driving the divergence not fully defined","Long-term in vivo consequences not addressed"]},{"year":2018,"claim":"Decisively dissociated FGF1 anti-apoptotic activity from FGFR kinase signaling and tied it to nucleolin-dependent nuclear phosphorylation.","evidence":"FGFR kinase inhibitors, kinase-dead FGFR1, translocation inhibitors, nucleolin-binding mutants, apoptosis assays across cell lines","pmids":["30099027"],"confidence":"High","gaps":["Direct nuclear targets beyond p53 not enumerated","Quantitative contribution of intracrine vs. receptor pathways in vivo unknown"]},{"year":2018,"claim":"Identified CSPG4 (NG2) and CD44 as cell-surface FGF1-binding proteoglycans acting as reservoir/storage molecules beyond FGFRs.","evidence":"APEX2-FGF1 proximity labeling/proteomics, colocalization, heparin-binding mutant analysis","pmids":["29812912"],"confidence":"Medium","gaps":["Functional consequence of reservoir binding on signaling not quantified","Whether these modulate receptor presentation untested"]},{"year":2019,"claim":"Defined Erk1/2 and p38 as redundant negative-feedback kinases phosphorylating FRS2 to downregulate FGF1-induced FGFR1 signaling.","evidence":"Erk/p38 inhibition and anisomycin activation in NIH3T3 and U2OS-FGFR1 cells with phosphorylation Westerns","pmids":["31013829"],"confidence":"Medium","gaps":["FRS2 phosphosites not mapped","In vivo significance of feedback redundancy untested"]},{"year":2020,"claim":"Connected mechanical Piezo1 activation to FGF1 release driving FGFR1-dependent adipogenesis, establishing a mechanotransduction-to-FGF1 axis.","evidence":"adipocyte-specific Piezo1 knockout mice on high-fat diet, FGF1 release and FGFR1 activation assays","pmids":["32385276"],"confidence":"High","gaps":["Secretion route engaged by Piezo1 not specified","Link to known non-classical export machinery undefined"]},{"year":2021,"claim":"Identified AMPK-Nur77 as the required downstream axis for FGF1ΔHBS protection against diabetic cardiomyopathy via improved mitochondrial function.","evidence":"db/db and AMPK-null mice, FGF1ΔHBS administration, RNA-seq, mitochondrial assays","pmids":["33762571"],"confidence":"High","gaps":["How FGFR signaling activates AMPK not resolved","Receptor isoform mediating the response not identified"]},{"year":2022,"claim":"Established that peripheral FGF1 suppresses lipolysis and hepatic glucose production by activating PDE4D to inhibit cAMP-PKA, mechanistically distinct from insulin.","evidence":"in vivo FGF1 administration, phosphodiesterase activity and phosphoproteomics (PDE4D Ser44), pharmacological PDE4 inhibition","pmids":["34986332"],"confidence":"High","gaps":["How FGFR signaling converges on PDE4D Ser44 phosphorylation unresolved","Tissue-specific receptor requirement undefined"]},{"year":2022,"claim":"Defined the dual MEK1/2-Akt (acute GLUT4) and MEK1/2-transcriptional (GLUT1) mechanisms by which FGF1 drives adipocyte glucose uptake.","evidence":"3T3-L1 and adipose explants, FGF1 knockout mice, MEK1/2 and Akt inhibitors, GLUT trafficking assays","pmids":["36161959"],"confidence":"High","gaps":["Crosstalk node linking MEK1/2 to Akt not pinpointed","Receptor isoform driving uptake undefined"]},{"year":2022,"claim":"Linked FGF1/FGFR signaling to estradiol-independent estrogen receptor phosphorylation and glycolytic reprogramming in endocrine-resistant breast cancer.","evidence":"proteomics, phosphoproteomics, metabolic assays in breast cancer cells, validation in obese mouse tumors","pmids":["37608351"],"confidence":"Medium","gaps":["Direct kinase linking FGFR to ER phosphorylation unidentified","Causality of metabolic shift vs. correlation incompletely separated"]},{"year":2023,"claim":"Showed FGF1 reverses hepatic steatosis via an epigenetic mechanism: reduced DNMT3A recruitment derepresses IGFBP2, which mediates the metabolic benefit.","evidence":"FGF1 in HFD mice, DNMT3A ChIP, bisulfite sequencing, AAV-IGFBP2 knockdown epistasis","pmids":["36934380"],"confidence":"Medium","gaps":["How FGFR signaling controls DNMT3A locus occupancy unknown","Single lab"]},{"year":null,"claim":"How the receptor-dependent metabolic signaling arm (PDE4D, MEK1/2-Akt, AMPK, epigenetic IGFBP2) is mechanistically coupled to specific FGFR isoforms and co-receptors in each target tissue, and how this integrates with the intracrine nuclear pathway in vivo, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified map linking receptor isoform usage to tissue-specific metabolic effectors","Relative in vivo contribution of intracrine vs. receptor pathways unquantified","Structural basis of the suboptimal-dimerization metabolic signal undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[13,16,31]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[21,31]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[13,31]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,4,5]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[20,21,31]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,10]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,18,31]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[14,15,28]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,6,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,17]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[2,3]}],"complexes":["Cu2+-dependent FGF1 non-classical export complex (S100A13/SphK1/AHNAK2)","FGF1-FGFR-heparan sulfate signaling complex"],"partners":["S100A13","SPHK1","AHNAK2","LRRC59","NUCLEOLIN","P53","KPNA2","FGFR1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05230","full_name":"Fibroblast growth factor 1","aliases":["Acidic fibroblast growth factor","aFGF","Endothelial cell growth factor","ECGF","Heparin-binding growth factor 1","HBGF-1"],"length_aa":155,"mass_kda":17.5,"function":"Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as a potent mitogen in vitro. Acts as a ligand for FGFR1 and integrins. Binds to FGFR1 in the presence of heparin leading to FGFR1 dimerization and activation via sequential autophosphorylation on tyrosine residues which act as docking sites for interacting proteins, leading to the activation of several signaling cascades. Binds to integrin ITGAV:ITGB3. Its binding to integrin, subsequent ternary complex formation with integrin and FGFR1, and the recruitment of PTPN11 to the complex are essential for FGF1 signaling. Induces the phosphorylation and activation of FGFR1, FRS2, MAPK3/ERK1, MAPK1/ERK2 and AKT1 (PubMed:18441324, PubMed:20422052). Can induce angiogenesis (PubMed:23469107)","subcellular_location":"Secreted; Cytoplasm; Cytoplasm, cell cortex; Cytoplasm, cytosol; Nucleus","url":"https://www.uniprot.org/uniprotkb/P05230/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGF1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGF1","total_profiled":1310},"omim":[{"mim_id":"616807","title":"FAS-BINDING FACTOR 1; FBF1","url":"https://www.omim.org/entry/616807"},{"mim_id":"616419","title":"ADHESION G PROTEIN-COUPLED RECEPTOR L4; ADGRL4","url":"https://www.omim.org/entry/616419"},{"mim_id":"614854","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 59; LRRC59","url":"https://www.omim.org/entry/614854"},{"mim_id":"610207","title":"SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 9; SLC4A9","url":"https://www.omim.org/entry/610207"},{"mim_id":"608712","title":"PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, T; PTPRT","url":"https://www.omim.org/entry/608712"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":282.0}],"url":"https://www.proteinatlas.org/search/FGF1"},"hgnc":{"alias_symbol":["AFGF","ECGF","ECGFA","ECGFB","HBGF1","ECGF-beta","FGF-alpha","GLIO703"],"prev_symbol":["FGFA"]},"alphafold":{"accession":"P05230","domains":[{"cath_id":"2.80.10.50","chopping":"24-150","consensus_level":"high","plddt":96.9595,"start":24,"end":150}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05230","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05230-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05230-F1-predicted_aligned_error_v6.png","plddt_mean":90.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGF1","jax_strain_url":"https://www.jax.org/strain/search?query=FGF1"},"sequence":{"accession":"P05230","fasta_url":"https://rest.uniprot.org/uniprotkb/P05230.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05230/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05230"}},"corpus_meta":[{"pmid":"17032753","id":"PMC_17032753","title":"FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17032753","citation_count":301,"is_preprint":false},{"pmid":"14625381","id":"PMC_14625381","title":"The non-classical export routes: FGF1 and IL-1alpha point the way.","date":"2003","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/14625381","citation_count":163,"is_preprint":false},{"pmid":"32385276","id":"PMC_32385276","title":"Adipocyte Piezo1 mediates obesogenic adipogenesis through the FGF1/FGFR1 signaling pathway in mice.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32385276","citation_count":126,"is_preprint":false},{"pmid":"26138239","id":"PMC_26138239","title":"Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.","date":"2015","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/26138239","citation_count":109,"is_preprint":false},{"pmid":"33762571","id":"PMC_33762571","title":"FGF1ΔHBS prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK/Nur77 suppression.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33762571","citation_count":100,"is_preprint":false},{"pmid":"29268138","id":"PMC_29268138","title":"TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1.","date":"2017","source":"Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29268138","citation_count":99,"is_preprint":false},{"pmid":"9036931","id":"PMC_9036931","title":"Transfection with aFGF cDNA improves wound healing.","date":"1997","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9036931","citation_count":87,"is_preprint":false},{"pmid":"35764933","id":"PMC_35764933","title":"FGF1 alleviates LPS-induced acute lung injury via suppression of inflammation and oxidative stress.","date":"2022","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/35764933","citation_count":86,"is_preprint":false},{"pmid":"34986332","id":"PMC_34986332","title":"FGF1 and insulin control lipolysis by convergent pathways.","date":"2022","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34986332","citation_count":85,"is_preprint":false},{"pmid":"28664920","id":"PMC_28664920","title":"FGF1 - a new weapon to control type 2 diabetes mellitus.","date":"2017","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28664920","citation_count":85,"is_preprint":false},{"pmid":"28813681","id":"PMC_28813681","title":"Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28813681","citation_count":84,"is_preprint":false},{"pmid":"31189876","id":"PMC_31189876","title":"FGF1ΔHBS ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31189876","citation_count":82,"is_preprint":false},{"pmid":"17204151","id":"PMC_17204151","title":"VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.","date":"2007","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/17204151","citation_count":78,"is_preprint":false},{"pmid":"12427329","id":"PMC_12427329","title":"Peripheral nerve grafts and aFGF restore partial hindlimb function in adult paraplegic rats.","date":"2002","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/12427329","citation_count":76,"is_preprint":false},{"pmid":"7510570","id":"PMC_7510570","title":"aFGF, bFGF and flg mRNAs show distinct patterns of induction in the hippocampus following kainate-induced seizures.","date":"1994","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/7510570","citation_count":73,"is_preprint":false},{"pmid":"1379560","id":"PMC_1379560","title":"Effects of acidic and basic fibroblast growth factors (aFGF, bFGF) on glial precursor cell proliferation: age dependency and brain region specificity.","date":"1992","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/1379560","citation_count":70,"is_preprint":false},{"pmid":"8576258","id":"PMC_8576258","title":"The neurotrophic activity of fibroblast growth factor 1 (FGF1) depends on endogenous FGF1 expression and is independent of the mitogen-activated protein kinase cascade pathway.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8576258","citation_count":65,"is_preprint":false},{"pmid":"18293181","id":"PMC_18293181","title":"FGF-1: from biology through engineering to potential medical applications.","date":"2008","source":"Critical reviews in clinical laboratory sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18293181","citation_count":62,"is_preprint":false},{"pmid":"34358309","id":"PMC_34358309","title":"MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/34358309","citation_count":60,"is_preprint":false},{"pmid":"1722570","id":"PMC_1722570","title":"High-affinity binding and activation of a truncated FGF receptor by both aFGF and bFGF.","date":"1991","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1722570","citation_count":59,"is_preprint":false},{"pmid":"7510293","id":"PMC_7510293","title":"Up-regulation of aFGF expression in quiescent cells is related to cell survival.","date":"1994","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7510293","citation_count":57,"is_preprint":false},{"pmid":"7506107","id":"PMC_7506107","title":"GAP-43, aFGF, CCK and alpha- and beta-CGRP in rat spinal motoneurons subjected to axotomy and/or dorsal root severance.","date":"1993","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/7506107","citation_count":56,"is_preprint":false},{"pmid":"22321063","id":"PMC_22321063","title":"Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1.","date":"2012","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/22321063","citation_count":54,"is_preprint":false},{"pmid":"33360774","id":"PMC_33360774","title":"aFGF alleviates diabetic endothelial dysfunction by decreasing oxidative stress via Wnt/β-catenin-mediated upregulation of HXK2.","date":"2020","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33360774","citation_count":53,"is_preprint":false},{"pmid":"10938383","id":"PMC_10938383","title":"TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.","date":"2000","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10938383","citation_count":53,"is_preprint":false},{"pmid":"10629559","id":"PMC_10629559","title":"aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8.","date":"1999","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10629559","citation_count":49,"is_preprint":false},{"pmid":"7534069","id":"PMC_7534069","title":"bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement.","date":"1995","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7534069","citation_count":49,"is_preprint":false},{"pmid":"10098767","id":"PMC_10098767","title":"Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10098767","citation_count":46,"is_preprint":false},{"pmid":"28795363","id":"PMC_28795363","title":"Fibroblast Growth Factor Type 1 (FGF1)-Overexpressed Adipose-Derived Mesenchaymal Stem Cells (AD-MSCFGF1) Induce Neuroprotection and Functional Recovery in a Rat Stroke Model.","date":"2017","source":"Stem cell reviews and reports","url":"https://pubmed.ncbi.nlm.nih.gov/28795363","citation_count":46,"is_preprint":false},{"pmid":"3056106","id":"PMC_3056106","title":"Development and testing of radio and enzyme immunoassays for acidic fibroblast growth factor (aFGF).","date":"1988","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3056106","citation_count":44,"is_preprint":false},{"pmid":"12176126","id":"PMC_12176126","title":"Angiogenesis-independent cardioprotection in FGF-1 transgenic mice.","date":"2002","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/12176126","citation_count":44,"is_preprint":false},{"pmid":"19765618","id":"PMC_19765618","title":"FGF1 nuclear translocation is required for both its neurotrophic activity and its p53-dependent apoptosis protection.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19765618","citation_count":44,"is_preprint":false},{"pmid":"33957117","id":"PMC_33957117","title":"MiR-205-5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33957117","citation_count":43,"is_preprint":false},{"pmid":"19240689","id":"PMC_19240689","title":"Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia.","date":"2009","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19240689","citation_count":43,"is_preprint":false},{"pmid":"8916273","id":"PMC_8916273","title":"aFGF, bFGF and NGF differentially regulate neuropeptide expression in dorsal root ganglia after axotomy and induce autotomy.","date":"1996","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/8916273","citation_count":41,"is_preprint":false},{"pmid":"35378464","id":"PMC_35378464","title":"Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.","date":"2022","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35378464","citation_count":41,"is_preprint":false},{"pmid":"16165218","id":"PMC_16165218","title":"FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis.","date":"2005","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16165218","citation_count":41,"is_preprint":false},{"pmid":"20559689","id":"PMC_20559689","title":"Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis.","date":"2010","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20559689","citation_count":40,"is_preprint":false},{"pmid":"1280690","id":"PMC_1280690","title":"Endogenous aFGF expression and cellular changes after a demyelinating lesion in the spinal cord of adult normal mice: immunohistochemical study.","date":"1992","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/1280690","citation_count":39,"is_preprint":false},{"pmid":"9541212","id":"PMC_9541212","title":"Effects of aFGF, bFGF, TGFbeta1 and IGF-I on odontoblast differentiation in vitro.","date":"1998","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9541212","citation_count":38,"is_preprint":false},{"pmid":"16091747","id":"PMC_16091747","title":"FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16091747","citation_count":37,"is_preprint":false},{"pmid":"38474378","id":"PMC_38474378","title":"The Combination of Vascular Endothelial Growth Factor A (VEGF-A) and Fibroblast Growth Factor 1 (FGF1) Modified mRNA Improves Wound Healing in Diabetic Mice: An Ex Vivo and In Vivo Investigation.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38474378","citation_count":37,"is_preprint":false},{"pmid":"26887791","id":"PMC_26887791","title":"Cell surface localization of importin α1/KPNA2 affects cancer cell proliferation by regulating FGF1 signalling.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26887791","citation_count":36,"is_preprint":false},{"pmid":"29017078","id":"PMC_29017078","title":"FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer cells.","date":"2017","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/29017078","citation_count":35,"is_preprint":false},{"pmid":"8819125","id":"PMC_8819125","title":"Expression of FGF1 and FGFR1 in human melanoma tissues.","date":"1996","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/8819125","citation_count":34,"is_preprint":false},{"pmid":"28655615","id":"PMC_28655615","title":"lncRNA-Map2k4 sequesters miR-199a to promote FGF1 expression and spinal cord neuron growth.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28655615","citation_count":34,"is_preprint":false},{"pmid":"26362179","id":"PMC_26362179","title":"FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC) metastasis through epithelial-mesenchymal transition (EMT).","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26362179","citation_count":34,"is_preprint":false},{"pmid":"10766827","id":"PMC_10766827","title":"Requirement of phosphatidylinositol 3-kinase activity for translocation of exogenous aFGF to the cytosol and nucleus.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10766827","citation_count":33,"is_preprint":false},{"pmid":"2950245","id":"PMC_2950245","title":"Biomaterial pretreatment with ECGF to augment endothelial cell proliferation.","date":"1987","source":"Journal of vascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/2950245","citation_count":33,"is_preprint":false},{"pmid":"36235670","id":"PMC_36235670","title":"Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway.","date":"2022","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36235670","citation_count":32,"is_preprint":false},{"pmid":"11545311","id":"PMC_11545311","title":"Endothelial cell growth factor (ECGF) enmeshed with fibrin matrix enhances proliferation of EC in vitro.","date":"2001","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/11545311","citation_count":32,"is_preprint":false},{"pmid":"10683301","id":"PMC_10683301","title":"Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin.","date":"2000","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10683301","citation_count":32,"is_preprint":false},{"pmid":"11745459","id":"PMC_11745459","title":"FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11745459","citation_count":31,"is_preprint":false},{"pmid":"34990928","id":"PMC_34990928","title":"A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/34990928","citation_count":30,"is_preprint":false},{"pmid":"9751263","id":"PMC_9751263","title":"Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers.","date":"1998","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/9751263","citation_count":30,"is_preprint":false},{"pmid":"8972720","id":"PMC_8972720","title":"Tissue distribution of human gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced expression.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8972720","citation_count":28,"is_preprint":false},{"pmid":"32615540","id":"PMC_32615540","title":"Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32615540","citation_count":28,"is_preprint":false},{"pmid":"27858202","id":"PMC_27858202","title":"Computational drill down on FGF1-heparin interactions through methodological evaluation.","date":"2016","source":"Glycoconjugate journal","url":"https://pubmed.ncbi.nlm.nih.gov/27858202","citation_count":28,"is_preprint":false},{"pmid":"23647222","id":"PMC_23647222","title":"The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities.","date":"2013","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23647222","citation_count":28,"is_preprint":false},{"pmid":"26420862","id":"PMC_26420862","title":"FGF1 Mediates Overnutrition-Induced Compensatory β-Cell Differentiation.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26420862","citation_count":27,"is_preprint":false},{"pmid":"30099027","id":"PMC_30099027","title":"Translocation of Exogenous FGF1 and FGF2 Protects the Cell against Apoptosis Independently of Receptor Activation.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30099027","citation_count":27,"is_preprint":false},{"pmid":"24571920","id":"PMC_24571920","title":"FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24571920","citation_count":27,"is_preprint":false},{"pmid":"32617870","id":"PMC_32617870","title":"miR-143-3p inhibits proliferation and invasion of hepatocellular carcinoma cells by regulating its target gene FGF1.","date":"2020","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/32617870","citation_count":27,"is_preprint":false},{"pmid":"24530908","id":"PMC_24530908","title":"Identification of a novel aFGF-binding peptide with anti-tumor effect on breast cancer from phage display library.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24530908","citation_count":27,"is_preprint":false},{"pmid":"7686384","id":"PMC_7686384","title":"aFGF binding to low and high affinity receptors induces both aFGF and aFGF receptors dimerization.","date":"1993","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/7686384","citation_count":26,"is_preprint":false},{"pmid":"25560297","id":"PMC_25560297","title":"AHNAK2 Participates in the Stress-Induced Nonclassical FGF1 Secretion Pathway.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25560297","citation_count":26,"is_preprint":false},{"pmid":"38623988","id":"PMC_38623988","title":"Microneedle Patch for Transdermal Sequential Delivery of KGF-2 and aFGF to Enhance Burn Wound Therapy.","date":"2024","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38623988","citation_count":25,"is_preprint":false},{"pmid":"9563652","id":"PMC_9563652","title":"Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers.","date":"1998","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/9563652","citation_count":25,"is_preprint":false},{"pmid":"32453715","id":"PMC_32453715","title":"Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32453715","citation_count":25,"is_preprint":false},{"pmid":"29048426","id":"PMC_29048426","title":"FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29048426","citation_count":23,"is_preprint":false},{"pmid":"31264280","id":"PMC_31264280","title":"LncRNA TUG1 regulates FGF1 to enhance endothelial differentiation of adipose-derived stem cells by sponging miR-143.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31264280","citation_count":23,"is_preprint":false},{"pmid":"17643421","id":"PMC_17643421","title":"Sphingosine kinase 1 is a critical component of the copper-dependent FGF1 export pathway.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17643421","citation_count":23,"is_preprint":false},{"pmid":"27138904","id":"PMC_27138904","title":"Activation of Aurora A kinase through the FGF1/FGFR signaling axis sustains the stem cell characteristics of glioblastoma cells.","date":"2016","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27138904","citation_count":23,"is_preprint":false},{"pmid":"26844696","id":"PMC_26844696","title":"FGF1 C-terminal domain and phosphorylation regulate intracrine FGF1 signaling for its neurotrophic and anti-apoptotic activities.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/26844696","citation_count":22,"is_preprint":false},{"pmid":"12044971","id":"PMC_12044971","title":"Effects of IL6 and IL1beta on aFGF expression and excitotoxicity in NT2N cells.","date":"2002","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/12044971","citation_count":22,"is_preprint":false},{"pmid":"34092624","id":"PMC_34092624","title":"Circular RNA circLMF1 regulates PDGF-BB-induced proliferation and migration of human aortic smooth muscle cells by regulating the miR-125a-3p/VEGFA or FGF1 axis.","date":"2022","source":"Clinical hemorheology and microcirculation","url":"https://pubmed.ncbi.nlm.nih.gov/34092624","citation_count":22,"is_preprint":false},{"pmid":"36161959","id":"PMC_36161959","title":"Autocrine FGF1 signaling promotes glucose uptake in adipocytes.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36161959","citation_count":21,"is_preprint":false},{"pmid":"10587545","id":"PMC_10587545","title":"Autocrine induction of gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) and GLS-induced expression of matrix metalloproteinases in rheumatoid arthritis synoviocytes.","date":"1999","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10587545","citation_count":21,"is_preprint":false},{"pmid":"1693366","id":"PMC_1693366","title":"Characterization of the hamster DDT-1 cell aFGF/HGBF-I gene and cDNA and its modulation by steroids.","date":"1990","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1693366","citation_count":21,"is_preprint":false},{"pmid":"26947349","id":"PMC_26947349","title":"Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by aFGF-Loaded Heparin-Modified Microbubbles and UTMD Technique.","date":"2016","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26947349","citation_count":21,"is_preprint":false},{"pmid":"37608351","id":"PMC_37608351","title":"FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.","date":"2023","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/37608351","citation_count":20,"is_preprint":false},{"pmid":"12909236","id":"PMC_12909236","title":"Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy.","date":"2003","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/12909236","citation_count":20,"is_preprint":false},{"pmid":"29812912","id":"PMC_29812912","title":"Proximity Labeling by a Recombinant APEX2-FGF1 Fusion Protein Reveals Interaction of FGF1 with the Proteoglycans CD44 and CSPG4.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29812912","citation_count":20,"is_preprint":false},{"pmid":"22415835","id":"PMC_22415835","title":"Ciliogenic RFX transcription factors regulate FGF1 gene promoter.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22415835","citation_count":20,"is_preprint":false},{"pmid":"36110535","id":"PMC_36110535","title":"Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36110535","citation_count":20,"is_preprint":false},{"pmid":"34973992","id":"PMC_34973992","title":"Methacrylated gelatin shape-memorable cryogel subcutaneously delivers EPCs and aFGF for improved pressure ulcer repair in diabetic rat model.","date":"2021","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34973992","citation_count":20,"is_preprint":false},{"pmid":"32104478","id":"PMC_32104478","title":"Improving the protective effects of aFGF for peripheral nerve injury repair using sulfated chitooligosaccharides.","date":"2018","source":"Asian journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32104478","citation_count":20,"is_preprint":false},{"pmid":"31013829","id":"PMC_31013829","title":"Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31013829","citation_count":19,"is_preprint":false},{"pmid":"24595027","id":"PMC_24595027","title":"Nucleolin regulates phosphorylation and nuclear export of fibroblast growth factor 1 (FGF1).","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24595027","citation_count":19,"is_preprint":false},{"pmid":"7507349","id":"PMC_7507349","title":"Developmental regulation of acidic fibroblast growth factor (aFGF) expression in bovine retina.","date":"1993","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7507349","citation_count":19,"is_preprint":false},{"pmid":"19394961","id":"PMC_19394961","title":"Evaluation of aFGF/bFGF and FGF signaling pathway in the wall of varicose veins.","date":"2008","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/19394961","citation_count":18,"is_preprint":false},{"pmid":"30968602","id":"PMC_30968602","title":"Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection.","date":"2019","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/30968602","citation_count":18,"is_preprint":false},{"pmid":"21302306","id":"PMC_21302306","title":"Regulation of non-classical FGF1 release and FGF-dependent cell transformation by CBF1-mediated notch signaling.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21302306","citation_count":16,"is_preprint":false},{"pmid":"9630568","id":"PMC_9630568","title":"Production and oestrogen regulation of FGF1 in normal and cancer breast cells.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9630568","citation_count":16,"is_preprint":false},{"pmid":"35864158","id":"PMC_35864158","title":"LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35864158","citation_count":15,"is_preprint":false},{"pmid":"36934380","id":"PMC_36934380","title":"FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/36934380","citation_count":15,"is_preprint":false},{"pmid":"11271786","id":"PMC_11271786","title":"Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas.","date":"2001","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11271786","citation_count":15,"is_preprint":false},{"pmid":"33788387","id":"PMC_33788387","title":"RAGE: A potential therapeutic target during FGF1 treatment of diabetes-mediated liver injury.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33788387","citation_count":15,"is_preprint":false},{"pmid":"34552869","id":"PMC_34552869","title":"The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34552869","citation_count":14,"is_preprint":false},{"pmid":"35480860","id":"PMC_35480860","title":"Genetically engineered FGF1-sericin hydrogel material treats intrauterine adhesion and restores fertility in rat.","date":"2022","source":"Regenerative biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/35480860","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54383,"output_tokens":8993,"usd":0.149022,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18757,"output_tokens":7890,"usd":0.145517,"stage2_stop_reason":"end_turn"},"total_usd":0.294539,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"FGF1 non-classical export (lacking an N-terminal signal sequence) depends on Cu2+-dependent formation of multiprotein complexes containing the S100A13 protein, and the protein may translocate across the membrane as a 'molten globule'.\",\n      \"method\": \"Biochemical characterization of export complex components; copper chelation inhibition experiments\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple labs reporting S100A13 involvement, but abstract-level description limits mechanistic detail\",\n      \"pmids\": [\"14625381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Sphingosine kinase 1 (SphK1) is a component of the copper-dependent FGF1 non-classical export pathway: SphK1 forms a complex with FGF1 in a cell-free system in a copper-dependent manner, SphK1-null cells fail to release FGF1 under stress, and SphK1 overexpression rescues FGF1 release from inhibition by a copper chelator.\",\n      \"method\": \"Cell-free complex reconstitution, SphK1 knockout/overexpression, copper chelation rescue experiments\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-free reconstitution and genetic rescue, single lab\",\n      \"pmids\": [\"17643421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Translocation of exogenous aFGF from the cell surface to the cytosol and nucleus requires phosphatidylinositol 3-kinase (PI3K) activity; inhibition of PI3K by chemical inhibitors or dominant-negative PI3K blocks cytosolic and nuclear translocation of aFGF, and PI3K-inhibited cells retain a diphtheria toxin–aFGF fusion protein in the cytosol rather than allowing nuclear entry.\",\n      \"method\": \"PI3K chemical inhibition, dominant-negative PI3K expression, cell fractionation, farnesylation and PKC phosphorylation reporters for translocation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods (chemical inhibition, dominant-negative genetics, reporter translocation assays) in a single study\",\n      \"pmids\": [\"10766827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Nuclear import of exogenous FGF1 (after cytosolic translocation) requires the ER-anchored protein LRRC59, Ran GTPase, importin-α1 (Kpnα1), and importin-β1 (Kpnβ1), as well as a nuclear localization sequence (NLS) in FGF1. LRRC59 depletion by siRNA does not block cytosolic translocation but blocks nuclear import of FGF1; nuclear import of FGF2 is independent of LRRC59 but dependent on the same importins.\",\n      \"method\": \"siRNA knockdown of LRRC59, Kpnα1, Kpnβ1; cell fractionation; localization imaging; comparison with FGF2 import pathway\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA knockdowns with orthogonal readouts, including pathway comparison to discriminate specificity\",\n      \"pmids\": [\"22321063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Nucleolin binds directly to FGF1 (interaction confirmed by surface plasmon resonance and pulldown) at residues within the heparin-binding site; nucleolin is required for intranuclear phosphorylation of FGF1 by PKCδ, and this phosphorylation event is required for nuclear export of FGF1. In nucleolin-depleted cells, FGF1 enters the nucleus but is neither phosphorylated by PKCδ nor exported.\",\n      \"method\": \"Affinity pulldown, surface plasmon resonance, nucleolin siRNA depletion, FGF1 phosphomimetic and binding mutants, nuclear fractionation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding confirmed by SPR, mechanistic pathway confirmed with multiple mutants and knockdown, single lab\",\n      \"pmids\": [\"24595027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGF1 nuclear translocation (via its NLS) is required for both its neurotrophic/differentiation activity and its protection against p53-dependent apoptosis in PC12 cells; deletion of the NLS (FGF1ΔNLS) abolishes nuclear localization and both activities. Wild-type FGF1 interacts with p53 (co-immunoprecipitation), whereas ΔNLS-FGF1 does not.\",\n      \"method\": \"Transfection of FGF1 NLS-deletion mutants, nuclear fractionation/imaging, co-immunoprecipitation of FGF1 with p53, differentiation and survival assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutant transfection with functional readouts plus co-IP, single lab\",\n      \"pmids\": [\"19765618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Intracellular (intracrine) FGF1 inhibits p53-dependent apoptosis and cell growth arrest via an intracrine pathway; it increases MDM2 expression (mRNA and protein), accelerating p53 degradation, and prevents Bax transactivation by p53. p53 activation represses FGF1 gene expression. Extracellular FGF1 has no effect on p53-dependent pathways.\",\n      \"method\": \"Transfection of intracellular vs. extracellular FGF1 constructs in rat embryonic fibroblasts; apoptosis/cell cycle assays; Western blot and RT-PCR for MDM2 and p53 targets\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic gain-of-function with multiple downstream readouts, single lab\",\n      \"pmids\": [\"16091747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FGF1 C-terminal residue K132 and phosphorylation of S130 regulate intracrine FGF1 anti-apoptotic activity in PC12 cells: K132E mutation abolishes both neurotrophic and anti-apoptotic activities; FGF1(S130A) (non-phosphorylatable) protects against p53-dependent apoptosis, whereas FGF1(S130D) (phosphomimetic) does not, indicating that phosphorylation inhibits anti-apoptotic activity but does not affect neurotrophic/differentiation activity.\",\n      \"method\": \"Transfection of FGF1 point mutants (K132E, S130A, S130D) in PC12 cells; differentiation and apoptosis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic mutagenesis with differentiated functional readouts, single lab\",\n      \"pmids\": [\"26844696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation at S130 and the C-terminal domain (K132). FGF1 phosphorylation status determines intracrine (but not extracellular pathway) anti-apoptotic activity; this effect is cell-type specific (absent in N2a cells).\",\n      \"method\": \"Recombinant FGF1 addition and FGF1 overexpression with point mutants (K132E, S130A, S130D) in SH-SY5Y and N2a cells; apoptosis assays; etoposide treatment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic mutagenesis with orthogonal cell-type comparison, single lab\",\n      \"pmids\": [\"29048426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Intracellular FGF1 (translocated from endosomes into the cytosol/nucleus) protects cells against apoptosis independently of FGFR activation and downstream signaling; this anti-apoptotic effect is abolished by inhibitors of endosome-to-cytosol translocation but not by potent FGFR kinase inhibitors. FGF1 mutations preventing binding to nucleolin (thereby preventing nuclear phosphorylation) reduce the anti-apoptotic activity, linking nuclear phosphorylation to anti-apoptotic function.\",\n      \"method\": \"FGFR kinase inhibitors, FGFR1 kinase-dead mutant, translocation inhibitors, nucleolin-binding FGF1 mutants; serum starvation and staurosporine apoptosis assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal pharmacological and genetic perturbations dissecting receptor-dependent vs. receptor-independent activities, replicated across multiple cell lines\",\n      \"pmids\": [\"30099027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AHNAK2 associates with FGF1 in a heat-shock-dependent manner (identified by co-immunoprecipitation/mass spectrometry); AHNAK2 depletion drastically decreases stress-induced FGF1 export but does not affect spontaneous FGF2 export or Notch-inhibition-induced FGF1 release, placing AHNAK2 specifically in the stress-induced non-classical FGF1 export pathway.\",\n      \"method\": \"Immunoprecipitation/mass spectrometry, AHNAK2 siRNA depletion, subcellular fractionation, FGF1 export assays under heat shock\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP/MS identification plus functional siRNA validation, single lab\",\n      \"pmids\": [\"25560297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Non-classical FGF1 release and FGF1-dependent cell transformation are regulated by Notch signaling through transcription factor CBF1: dominant-negative CBF1 induces FGF1 and SphK1 transcription and stimulates stress-independent FGF1 release; the transformed phenotype of dnCBF1 cells is blocked by dominant-negative FGFR1 or dominant-negative S100A13; FGF1 export and cell proliferation induced by dnCBF1 depend on SphK1.\",\n      \"method\": \"Dominant-negative CBF1 and MAML transfection, colony formation assay, tumor xenograft, FGF1 export assay, FGF1-null cells\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis using dominant-negative constructs and null cells, multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"21302306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"FGF1 neurotrophic activity (neuronal differentiation and serum-free survival) in PC12 cells requires endogenous FGF1 expression and is independent of the MAP kinase cascade; MAP kinase (ERK1) is activated equally by FGF1, FGF1+heparin, and a mutated FGF1, but only FGF1+heparin promotes differentiation. Constitutive or inducible overexpression of FGF1 directly promotes differentiation and survival proportional to the level of FGF1 expressed.\",\n      \"method\": \"MAP kinase activation assays, PC12 differentiation assays, FGF1 transfection with constitutive and inducible expression vectors, serum-free survival\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical pathway dissection with transfection gain-of-function, single lab\",\n      \"pmids\": [\"8576258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"An FGF1 partial agonist carrying triple mutations (FGF1ΔHBS) that diminish heparan sulfate (HS)-assisted FGFR dimerization has severely reduced mitogenic/proliferative activity while retaining full metabolic activity; this establishes that stable FGFR dimerization is required for mitogenesis but suboptimal FGFR activation by a weak FGF1-FGFR dimer is sufficient for metabolic responses (glucose homeostasis).\",\n      \"method\": \"Site-directed mutagenesis of heparin-binding site, in vitro proliferation assays, in vivo metabolic assays in mice, receptor dimerization assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution-level mutagenesis with orthogonal in vitro and in vivo functional dissection of two distinct biological activities\",\n      \"pmids\": [\"28813681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF1 acutely suppresses adipose lipolysis and hepatic glucose production by inhibiting the cAMP-PKA axis through activation of phosphodiesterase 4D (PDE4D), which is mechanistically distinct from insulin's inhibitory action via PDE3B. FGF1-induced Ser44 phosphorylation of PDE4D is a regulatory site modulated by the feed-fast cycle.\",\n      \"method\": \"In vivo FGF1 administration with lipolysis and hepatic glucose production assays; phosphodiesterase activity assays; phosphoproteomics identifying PDE4D Ser44; pharmacological PDE4 inhibition\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical and in vivo methods, identification of specific phosphorylation site, mechanistic distinction from insulin pathway\",\n      \"pmids\": [\"34986332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF1 increases glucose uptake in adipocytes via two mechanisms: acutely, through MEK1/2 and Akt crosstalk activating the insulin-sensitive glucose transporter GLUT4; and with prolonged exposure, through MEK1/2-dependent transcriptional upregulation of the basal glucose transporter GLUT1. FGF1 knockout mice have reduced adipose glucose uptake.\",\n      \"method\": \"FGF1 treatment of 3T3-L1 adipocytes and ex vivo adipose explants; FGF1 knockout mice; MEK1/2 and Akt inhibitors; GLUT1/GLUT4 expression and trafficking assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse phenotype confirmed in ex vivo and in vitro, pharmacological pathway dissection, multiple orthogonal readouts\",\n      \"pmids\": [\"36161959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In adipocytes, mechanical activation of Piezo1 causes release of FGF1, which then induces preadipocyte differentiation (adipogenesis) through activation of FGF receptor 1 (FGFR1). Mice lacking Piezo1 in mature adipocytes show defective preadipocyte differentiation under high-fat diet.\",\n      \"method\": \"Adipocyte-specific Piezo1 knockout mice on high-fat diet; FGF1 release assays; FGFR1 activation assays; preadipocyte differentiation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout mouse with clearly defined cellular phenotype and receptor-ligand pathway validated, replicated across conditions\",\n      \"pmids\": [\"32385276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In zebrafish, Fgf1 signaling is necessary and sufficient for overnutrition-induced compensatory β-cell differentiation: fgf1 inactivation abolishes compensatory β-cell differentiation; expression of human FGF1 solely in β-cells rescues the response in fgf1-/- animals; constitutive FGF1 secretion with an exogenous signal peptide increases β-cell number without overnutrition. FGF1 is secreted from β-cells during prolonged activation, with ER stress acting upstream of FGF1 release.\",\n      \"method\": \"Zebrafish fgf1 loss-of-function and rescue genetics, constitutive FGF1 secretion construct, small-molecule screen, β-cell differentiation assay, ER stress manipulation\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic necessity and sufficiency established with rescue experiments, orthologous context consistent with mammalian FGF1\",\n      \"pmids\": [\"26420862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGFR-1 interacts with the TNF receptor superfamily member Fn14 (co-immunoprecipitation and proximity ligation assay in cardiomyocytes); FGF1-induced cardiomyocyte cell cycle reentry is blocked by Fn14 inhibition, and TWEAK-induced cell cycle activation is blocked by FGFR-1 inhibition; costimulation with FGF1 and TWEAK synergistically induces cell cycle reentry via PI3K/Akt signaling.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, Fn14 siRNA inhibition, FGFR-1 blockade, PI3K/Akt pathway analysis, cardiomyocyte cell cycle assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction confirmed by two orthogonal methods plus functional blockade, single lab\",\n      \"pmids\": [\"24571920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cardiac-specific overexpression of FGF1 in transgenic mice delays infarct development and provides cardiomyocyte-level protection independently of angiogenesis, at least partially through constitutively elevated ERK-1/2 activity; ERK-1/2 inhibitor (UO126) reduces the cardioprotective effect.\",\n      \"method\": \"Transgenic mouse coronary occlusion model, infarct size measurement, ERK-1/2 Western blot, ERK inhibitor treatment, isolated cardiomyocyte ischemia simulation\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse model with pharmacological pathway validation, multiple readouts, single lab\",\n      \"pmids\": [\"12176126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Cell-surface-localized importin α1 (KPNA2) binds directly to FGF1 (a cNLS-containing growth factor) and enhances ERK1/2 activation downstream of FGF1 signaling; anti-importin α1 antibody suppresses FGF1-importin α1 complex formation and ERK1/2 activation, reducing cancer cell proliferation.\",\n      \"method\": \"Cell surface importin α1 detection, co-immunoprecipitation of importin α1 with FGF1, ERK1/2 phosphorylation assays, anti-importin α1 antibody inhibition, proliferation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding shown by co-IP, functional consequence confirmed by antibody blockade, single lab\",\n      \"pmids\": [\"26887791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FGF1 binds cell-surface proteoglycans CSPG4 (NG2) and CD44 in addition to FGFRs; FGF1 binds CD44 through its heparin-binding moiety; both CSPG4 and CD44 colocalize with FGF1 at the cell surface and likely act as storage/reservoir molecules for FGF1.\",\n      \"method\": \"APEX2-FGF1 proximity labeling on living cells followed by proteomics; signaling validation of fusion protein; colocalization imaging; heparin-binding domain mutant analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity labeling plus domain-mapping mutagenesis and colocalization, single lab\",\n      \"pmids\": [\"29812912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Both high-affinity aFGF (and bFGF) binding and receptor activation by aFGF/bFGF do not require the N-terminal first Ig-like domain and acidic motif of the FGFR (bek/FGFR2); a truncated bek variant lacking these regions is sufficient for high-affinity binding and cell activation.\",\n      \"method\": \"cDNA cloning and overexpression of truncated FGFR variants in NIH3T3 cells; FGF binding assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor domain deletion with ligand-binding and activation readouts, single study\",\n      \"pmids\": [\"1722570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"aFGF and bFGF induce membrane ruffling in breast cancer cells (but not normal breast epithelial cells) through FGFR-4; dominant-negative FGFR-3 or dominant-negative p21rac inhibits membrane ruffling, establishing that receptor dimerization/phosphorylation and Rac activation are prerequisites; transient transfection showed FGFR-1, -2, -3 cannot mediate ruffling while FGFR-4 can.\",\n      \"method\": \"Dominant-negative FGFR3 and Rac transfection, transient transfection of individual FGFRs in COS-7 cells, morphological membrane ruffling assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative genetics and receptor isoform transfection, single lab\",\n      \"pmids\": [\"7534069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FGF-1 (and FGF-2) upregulate E-cadherin, β-catenin, and α-catenin protein levels in pancreatic cancer cells and facilitate the association of E-cadherin and α-catenin with the cytoskeleton (shown by increased detergent-insoluble fraction). FGFs also elevate tyrosine phosphorylation of E-cadherin, α-, β-, and γ-catenins (but not p120ctn), suggesting FGF/FGFR signaling regulates the E-cadherin/catenin complex.\",\n      \"method\": \"FGF-1 treatment of pancreatic cancer cell lines, Western blot for cadherin/catenin levels, Triton X-100 fractionation for cytoskeletal association, tyrosine phosphorylation Western blot\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple cell lines and multiple biochemical readouts but no genetic confirmation, single lab\",\n      \"pmids\": [\"11745459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Both Erk1/2 and p38 kinase phosphorylate FRS2 (a major FGFR1 signaling mediator) as part of negative-feedback downregulation of FGF1-induced signaling. Simultaneous inhibition of both Erk1/2 and p38 produces significantly prolonged FGFR1 and FRS2 tyrosine phosphorylation compared to Erk inhibition alone, and excessive p38 activation can partially compensate for absent Erk activity.\",\n      \"method\": \"Pharmacological inhibition of Erk1/2 and/or p38 in NIH3T3 and U2OS-FGFR1 cells; anisomycin p38 activation; Western blot for FGFR1 and FRS2 phosphorylation\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway crosstalk with orthogonal activator/inhibitor design, single lab\",\n      \"pmids\": [\"31013829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The FGF1 gene 1B promoter is activated by valproic acid (VPA) through inhibition of HDAC (histone deacetylases) and GSK-3 activities; VPA causes increased histone H3 acetylation at an 18-bp cis-element of the FGF-1B promoter and alters RFX1-3 transcriptional complex binding.\",\n      \"method\": \"FGF-1B promoter-GFP reporter, HDAC and GSK-3 inhibitors (sodium butyrate, trichostatin A, lithium), GSK-3 siRNA, ChIP for histone acetylation\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitors and siRNA confirmed with ChIP, single lab\",\n      \"pmids\": [\"23647222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RFX1, RFX2, and RFX3 transcription factors directly bind an 18-bp cis-element (-484 to -467) in the human FGF1 gene 1B promoter to regulate its activity; RFX2/RFX3 complex is detected only in FGF-1B positive cells; RFX2 knockdown reduces FGF-1B(+) cell proportion and neurosphere formation while RFX2 overexpression has opposite effects.\",\n      \"method\": \"Promoter-reporter assays, ChIP/EMSA for RFX binding, RFX2 siRNA knockdown and overexpression, neurosphere assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed, genetic gain/loss-of-function, single lab\",\n      \"pmids\": [\"22415835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FGF1 ameliorates hepatic steatosis by inducing IGFBP2 expression through reducing recruitment of DNA methyltransferase 3α (DNMT3A) to the IGFBP2 genomic locus, decreasing IGFBP2 gene methylation and increasing its expression; AAV-mediated IGFBP2 suppression diminishes the therapeutic benefit of FGF1 on hepatic steatosis, demonstrating that this epigenetic IGFBP2 pathway mediates FGF1 metabolic action.\",\n      \"method\": \"Recombinant FGF1 treatment in HFD mice, ChIP for DNMT3A at IGFBP2 locus, bisulfite sequencing for methylation, AAV-IGFBP2 knockdown epistasis, palmitic acid hepatocyte model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and methylation analysis with in vivo epistasis, single lab\",\n      \"pmids\": [\"36934380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FGF1/FGFR signaling activates Aurora A (AurA) kinase (Thr288 phosphorylation) in glioblastoma cells; FGFR inhibitor (SU5402) down-regulates AurA activity and AurA inhibitors reduce neurosphere formation and induce neuronal differentiation of FGF1B(+) GBM cells.\",\n      \"method\": \"FGF1 treatment and FGFR inhibition in GBM cell lines, AurA phosphorylation Western blot, FACS isolation of F1BGFP+ cells, neurosphere assays, AurA inhibitors\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition of FGFR and AurA with multiple orthogonal functional readouts, single lab\",\n      \"pmids\": [\"27138904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FGF1ΔHBS (reduced heparin-binding, low-mitogenicity variant) protects against diabetic cardiomyopathy by activating AMPK, which suppresses Nur77 expression, leading to reduced mitochondrial fragmentation, ROS, and cytochrome c leakage and enhanced mitochondrial respiration; protective effects are absent in AMPK-null mice, establishing AMPK as a required downstream mediator.\",\n      \"method\": \"db/db mouse model, FGF1ΔHBS administration, RNA-seq, AMPK knockout mice, mitochondrial function assays, ROS and apoptosis assays in vitro and in vivo\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — AMPK-null mouse epistasis confirms pathway requirement, multiple orthogonal in vitro and in vivo readouts, single lab\",\n      \"pmids\": [\"33762571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"aFGF binding to cell-surface receptors induces both high-affinity receptor (HAR/FGFR1) dimerization and aFGF homodimerization; the 150 kDa HAR-aFGF complex is proposed to consist of one FGFR1 associated with one heparan sulfate proteoglycan (LAR) via aFGF dimerization. Heparin suppresses formation of the 150 kDa complex and the aFGF dimer on LAR. An aFGF mutant with reduced heparin affinity does not promote dimerization. Only HAR (not LAR) directly mediates aFGF internalization.\",\n      \"method\": \"Cross-linking experiments with 125I-aFGF, receptor binding and internalization assays, heparin competition, aFGF mutant with reduced heparin affinity\",\n      \"journal\": \"Growth factors (Chur, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cross-linking and binding studies with heparin competition and mutant, single lab\",\n      \"pmids\": [\"7686384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF1 promotes a glycolytic metabolic phenotype in endocrine-resistant breast cancer cells by stimulating estrogen receptor (ER) phosphorylation independently of estradiol; this estrogen-independent ER activation and metabolic reprogramming involves the FGF/FGFR axis.\",\n      \"method\": \"Untargeted proteomics, phospho-proteomics, gene expression profiling, functional metabolic assessments in breast cancer cells; validated in obese mouse tumor samples\",\n      \"journal\": \"Breast cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal omics and functional metabolic assays, single lab\",\n      \"pmids\": [\"37608351\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGF1 is a heparin-binding growth factor that signals through cell-surface FGF receptors (requiring HS-assisted FGFR dimerization for full mitogenic activation, while suboptimal dimerization is sufficient for metabolic responses), and also operates via a receptor-independent intracrine/nuclear pathway in which exogenous FGF1 is endocytosed, translocated to the cytosol via PI3K-dependent vesicular transport, imported into the nucleus via LRRC59/importin-α1/β1, where it interacts with nucleolin leading to PKCδ-mediated phosphorylation at S130 (which triggers nuclear export) and directly interacts with p53 to suppress apoptosis; metabolically, peripheral FGF1 acutely suppresses lipolysis and hepatic glucose production by activating PDE4D (suppressing cAMP-PKA signaling), promotes adipocyte glucose uptake through GLUT4/GLUT1 via MEK1/2-Akt crosstalk, and is released non-classically from cells without a signal peptide through a Cu2+- and S100A13-dependent pathway involving sphingosine kinase 1 and AHNAK2, regulated upstream by Notch/CBF1 signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGF1 is a heparin-binding growth factor that operates through two distinct arms: canonical signaling via cell-surface FGF receptors and a receptor-independent intracrine/nuclear pathway, and it has emerged as a potent regulator of systemic metabolism [#13, #14]. At the receptor, FGF1 binding induces FGFR and ligand homodimerization in a heparin-/heparan sulfate-dependent manner [#31], and an engineered variant with diminished heparan-sulfate-assisted FGFR dimerization (FGF1\\u0394HBS) retains full metabolic activity while losing mitogenic potency, establishing that stable receptor dimerization drives proliferation whereas suboptimal dimerization suffices for metabolic responses [#13]. Metabolically, peripheral FGF1 acutely suppresses adipose lipolysis and hepatic glucose production by activating phosphodiesterase 4D to inhibit the cAMP-PKA axis\\u2014mechanistically distinct from insulin's action via PDE3B [#14]\\u2014and promotes adipocyte glucose uptake through MEK1/2-Akt crosstalk acting on GLUT4 and transcriptional induction of GLUT1 [#15]. In a parallel intracrine route, exogenous FGF1 is endocytosed and translocated to the cytosol in a PI3K-dependent manner [#2], imported into the nucleus via the ER-anchored protein LRRC59 together with importin-\\u03b11/\\u03b21 and Ran [#3], where it binds nucleolin to enable PKC\\u03b4-mediated phosphorylation at S130 that triggers nuclear export [#4]; nuclear FGF1 interacts with p53 and suppresses p53-dependent apoptosis independently of FGFR kinase activity [#5, #9]. FGF1 is secreted by a non-classical, signal-peptide-independent route that requires Cu2+-dependent assembly with S100A13, sphingosine kinase 1, and AHNAK2 [#0, #1, #10], a pathway transcriptionally restrained by Notch/CBF1 signaling [#11]. Across tissues these activities underlie roles in \\u03b2-cell compensatory differentiation [#17], cardiomyocyte protection and proliferation [#19], adipogenesis downstream of mechanical Piezo1 activation [#16], and reversal of hepatic steatosis [#28].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Defined which FGFR regions are dispensable for FGF1 high-affinity binding and activation, refining the receptor-ligand engagement model.\",\n      \"evidence\": \"truncated FGFR2 (bek) variant expression and binding assays in NIH3T3 cells\",\n      \"pmids\": [\"1722570\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not resolve the structural basis of dimerization\", \"Single receptor isoform tested\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that FGF1 receptor activation proceeds through heparin-modulated FGFR and ligand dimerization, defining the assembly logic of the signaling complex.\",\n      \"evidence\": \"crosslinking of 125I-aFGF, heparin competition, and a reduced-heparin-affinity mutant\",\n      \"pmids\": [\"7686384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Complex stoichiometry inferred rather than structurally resolved\", \"Role of specific heparan sulfate proteoglycan not defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed FGF1 neurotrophic/survival activity can be uncoupled from MAP kinase activation, hinting at a receptor-independent intracellular mode.\",\n      \"evidence\": \"PC12 differentiation assays with FGF1 transfection and MAP kinase activation readouts\",\n      \"pmids\": [\"8576258\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Intracellular site of action not localized\", \"Effector of the MAPK-independent activity unknown at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified PI3K as a requirement for translocation of exogenous FGF1 from the cell surface to the cytosol and nucleus, opening the intracrine trafficking pathway.\",\n      \"evidence\": \"PI3K chemical inhibition, dominant-negative PI3K, cell fractionation and translocation reporters\",\n      \"pmids\": [\"10766827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of PI3K-dependent vesicular machinery undefined\", \"Step at which FGF1 crosses the membrane unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Characterized FGF1 non-classical export as a Cu2+-dependent multiprotein process involving S100A13, addressing how a signal-peptide-less protein is released.\",\n      \"evidence\": \"biochemical export complex characterization and copper chelation inhibition\",\n      \"pmids\": [\"14625381\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molten-globule translocation mechanism not directly demonstrated\", \"In vivo relevance of copper dependence unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated that intracellular FGF1 suppresses p53-dependent apoptosis by raising MDM2 and blocking Bax transactivation, establishing an intracrine anti-apoptotic function.\",\n      \"evidence\": \"intracellular vs. extracellular FGF1 constructs in rat embryonic fibroblasts with apoptosis and target gene readouts\",\n      \"pmids\": [\"16091747\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect FGF1-p53 interaction not shown here\", \"Mechanism of MDM2 induction undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Placed sphingosine kinase 1 in the copper-dependent FGF1 export complex, expanding the non-classical secretion machinery.\",\n      \"evidence\": \"cell-free reconstitution, SphK1 knockout/overexpression, copper-chelation rescue\",\n      \"pmids\": [\"17643421\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymatic vs. structural role of SphK1 not separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linked the FGF1 NLS to both neurotrophic and anti-apoptotic activity and showed wild-type but not \\u0394NLS FGF1 co-immunoprecipitates with p53.\",\n      \"evidence\": \"NLS-deletion mutants, fractionation/imaging, FGF1-p53 co-IP, survival assays in PC12 cells\",\n      \"pmids\": [\"19765618\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding not confirmed (co-IP only)\", \"Whether nuclear entry alone or downstream events drive protection unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the nuclear import machinery for cytosolic FGF1 as LRRC59/importin-\\u03b11/\\u03b21/Ran, distinguishing it from FGF2 import.\",\n      \"evidence\": \"siRNA knockdown of LRRC59 and importins with fractionation and pathway comparison\",\n      \"pmids\": [\"22321063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ER-anchored LRRC59 hands off FGF1 to importins mechanistically unclear\", \"Cytosol-to-nucleus shuttling kinetics undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified RFX1-3 transcription factors binding an 18-bp cis-element of the FGF1 1B promoter as direct regulators of FGF1 expression in neural cells.\",\n      \"evidence\": \"promoter-reporter, ChIP/EMSA, RFX2 knockdown/overexpression with neurosphere assays\",\n      \"pmids\": [\"22415835\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific signals controlling RFX complex assembly unknown\", \"Other FGF1 promoters not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed the FGF1 1B promoter is epigenetically activated via HDAC and GSK-3 inhibition through RFX-bound chromatin, connecting chromatin state to FGF1 induction.\",\n      \"evidence\": \"promoter reporter, HDAC/GSK-3 inhibitors, GSK-3 siRNA, histone acetylation ChIP\",\n      \"pmids\": [\"23647222\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological stimulus engaging this axis unknown\", \"Direct HDAC isoform not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established nucleolin as a direct FGF1 partner required for PKC\\u03b4 phosphorylation of FGF1 and subsequent nuclear export, defining the intranuclear processing step.\",\n      \"evidence\": \"SPR, affinity pulldown, nucleolin siRNA, FGF1 binding and phosphomimetic mutants, fractionation\",\n      \"pmids\": [\"24595027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How nucleolin positions FGF1 for PKC\\u03b4 not structurally resolved\", \"PKC\\u03b4 recruitment mechanism undefined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified an FGFR1-Fn14 receptor interaction enabling synergistic FGF1/TWEAK-driven cardiomyocyte cell cycle reentry via PI3K/Akt.\",\n      \"evidence\": \"co-IP, proximity ligation, Fn14 and FGFR-1 inhibition, cell cycle assays in cardiomyocytes\",\n      \"pmids\": [\"24571920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether interaction is direct or scaffold-mediated unknown\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Added AHNAK2 as a stress-induced, heat-shock-dependent component specifically required for non-classical FGF1 (not FGF2) export.\",\n      \"evidence\": \"co-IP/MS identification, AHNAK2 siRNA, fractionation and export assays\",\n      \"pmids\": [\"25560297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular role of AHNAK2 in translocation unknown\", \"Interplay with S100A13/SphK1 complex undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated in zebrafish that Fgf1 is necessary and sufficient for overnutrition-induced compensatory \\u03b2-cell differentiation, establishing a physiological metabolic role for secreted FGF1.\",\n      \"evidence\": \"fgf1 loss-of-function and \\u03b2-cell rescue genetics, constitutive secretion construct, ER stress manipulation\",\n      \"pmids\": [\"26420862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and downstream effectors in \\u03b2-cells not defined here\", \"Mammalian conservation inferred, not directly shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed cell-surface importin \\u03b11 (KPNA2) binds FGF1 and enhances ERK1/2 activation and cancer cell proliferation, expanding importin function beyond nuclear import.\",\n      \"evidence\": \"surface importin \\u03b11 detection, FGF1 co-IP, antibody blockade, proliferation assays\",\n      \"pmids\": [\"26887791\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which surface importin potentiates ERK unclear\", \"Relationship to FGFR signaling complex undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked FGF1/FGFR signaling to Aurora A activation controlling neurosphere formation and differentiation state in glioblastoma.\",\n      \"evidence\": \"FGF1 treatment, FGFR and AurA pharmacological inhibition, neurosphere assays in GBM cells\",\n      \"pmids\": [\"27138904\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect AurA activation undefined\", \"Pharmacological inhibitors only\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapped FGF1 K132 and S130 phosphorylation as switches controlling intracrine anti-apoptotic versus neurotrophic activities.\",\n      \"evidence\": \"K132E/S130A/S130D point mutants in PC12 cells with differentiation and apoptosis assays\",\n      \"pmids\": [\"26844696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural consequence of phosphorylation not determined\", \"Kinase responsible inferred from prior work\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Confirmed the S130-phosphorylation-dependent, cell-type-specific intracrine anti-apoptotic pathway in neuroblastoma cells.\",\n      \"evidence\": \"recombinant and overexpressed FGF1 mutants in SH-SY5Y vs. N2a cells, etoposide apoptosis assays\",\n      \"pmids\": [\"29048426\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis of cell-type specificity unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Separated mitogenic from metabolic FGF1 activity using FGF1\\u0394HBS, showing stable FGFR dimerization is required for proliferation but not for glucose homeostasis\\u2014a foundation for safer metabolic therapeutics.\",\n      \"evidence\": \"heparin-binding-site mutagenesis, in vitro proliferation and in vivo metabolic and dimerization assays\",\n      \"pmids\": [\"28813681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor signaling differences driving the divergence not fully defined\", \"Long-term in vivo consequences not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Decisively dissociated FGF1 anti-apoptotic activity from FGFR kinase signaling and tied it to nucleolin-dependent nuclear phosphorylation.\",\n      \"evidence\": \"FGFR kinase inhibitors, kinase-dead FGFR1, translocation inhibitors, nucleolin-binding mutants, apoptosis assays across cell lines\",\n      \"pmids\": [\"30099027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct nuclear targets beyond p53 not enumerated\", \"Quantitative contribution of intracrine vs. receptor pathways in vivo unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified CSPG4 (NG2) and CD44 as cell-surface FGF1-binding proteoglycans acting as reservoir/storage molecules beyond FGFRs.\",\n      \"evidence\": \"APEX2-FGF1 proximity labeling/proteomics, colocalization, heparin-binding mutant analysis\",\n      \"pmids\": [\"29812912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of reservoir binding on signaling not quantified\", \"Whether these modulate receptor presentation untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined Erk1/2 and p38 as redundant negative-feedback kinases phosphorylating FRS2 to downregulate FGF1-induced FGFR1 signaling.\",\n      \"evidence\": \"Erk/p38 inhibition and anisomycin activation in NIH3T3 and U2OS-FGFR1 cells with phosphorylation Westerns\",\n      \"pmids\": [\"31013829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FRS2 phosphosites not mapped\", \"In vivo significance of feedback redundancy untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected mechanical Piezo1 activation to FGF1 release driving FGFR1-dependent adipogenesis, establishing a mechanotransduction-to-FGF1 axis.\",\n      \"evidence\": \"adipocyte-specific Piezo1 knockout mice on high-fat diet, FGF1 release and FGFR1 activation assays\",\n      \"pmids\": [\"32385276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Secretion route engaged by Piezo1 not specified\", \"Link to known non-classical export machinery undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified AMPK-Nur77 as the required downstream axis for FGF1\\u0394HBS protection against diabetic cardiomyopathy via improved mitochondrial function.\",\n      \"evidence\": \"db/db and AMPK-null mice, FGF1\\u0394HBS administration, RNA-seq, mitochondrial assays\",\n      \"pmids\": [\"33762571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FGFR signaling activates AMPK not resolved\", \"Receptor isoform mediating the response not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established that peripheral FGF1 suppresses lipolysis and hepatic glucose production by activating PDE4D to inhibit cAMP-PKA, mechanistically distinct from insulin.\",\n      \"evidence\": \"in vivo FGF1 administration, phosphodiesterase activity and phosphoproteomics (PDE4D Ser44), pharmacological PDE4 inhibition\",\n      \"pmids\": [\"34986332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FGFR signaling converges on PDE4D Ser44 phosphorylation unresolved\", \"Tissue-specific receptor requirement undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the dual MEK1/2-Akt (acute GLUT4) and MEK1/2-transcriptional (GLUT1) mechanisms by which FGF1 drives adipocyte glucose uptake.\",\n      \"evidence\": \"3T3-L1 and adipose explants, FGF1 knockout mice, MEK1/2 and Akt inhibitors, GLUT trafficking assays\",\n      \"pmids\": [\"36161959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosstalk node linking MEK1/2 to Akt not pinpointed\", \"Receptor isoform driving uptake undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked FGF1/FGFR signaling to estradiol-independent estrogen receptor phosphorylation and glycolytic reprogramming in endocrine-resistant breast cancer.\",\n      \"evidence\": \"proteomics, phosphoproteomics, metabolic assays in breast cancer cells, validation in obese mouse tumors\",\n      \"pmids\": [\"37608351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase linking FGFR to ER phosphorylation unidentified\", \"Causality of metabolic shift vs. correlation incompletely separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed FGF1 reverses hepatic steatosis via an epigenetic mechanism: reduced DNMT3A recruitment derepresses IGFBP2, which mediates the metabolic benefit.\",\n      \"evidence\": \"FGF1 in HFD mice, DNMT3A ChIP, bisulfite sequencing, AAV-IGFBP2 knockdown epistasis\",\n      \"pmids\": [\"36934380\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How FGFR signaling controls DNMT3A locus occupancy unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the receptor-dependent metabolic signaling arm (PDE4D, MEK1/2-Akt, AMPK, epigenetic IGFBP2) is mechanistically coupled to specific FGFR isoforms and co-receptors in each target tissue, and how this integrates with the intracrine nuclear pathway in vivo, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified map linking receptor isoform usage to tissue-specific metabolic effectors\", \"Relative in vivo contribution of intracrine vs. receptor pathways unquantified\", \"Structural basis of the suboptimal-dimerization metabolic signal undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [13, 16, 31]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [21, 31]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [13, 31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [20, 21, 31]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 10]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 18, 31]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [14, 15, 28]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 6, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 17]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [\n      \"Cu2+-dependent FGF1 non-classical export complex (S100A13/SphK1/AHNAK2)\",\n      \"FGF1-FGFR-heparan sulfate signaling complex\"\n    ],\n    \"partners\": [\n      \"S100A13\",\n      \"SphK1\",\n      \"AHNAK2\",\n      \"LRRC59\",\n      \"nucleolin\",\n      \"p53\",\n      \"KPNA2\",\n      \"FGFR1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}